gliclazide has been researched along with Dyslipidemias in 5 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe one patient with diabetes mellitus treated by fenofibrate monotherapy since several years; 48 h after gliclazide therapy was introduced, rhabdomyolysis occurred." | 7.73 | [Rhabdomyolysis induced by fenofibrate monotherapy]. ( Amaniou, M; Archambeaud-Mouveroux, F; Combes, C; Galinat, S; Lassandre, S; Lopez, S; Teissier, MP, 2006) |
| "We describe one patient with diabetes mellitus treated by fenofibrate monotherapy since several years; 48 h after gliclazide therapy was introduced, rhabdomyolysis occurred." | 3.73 | [Rhabdomyolysis induced by fenofibrate monotherapy]. ( Amaniou, M; Archambeaud-Mouveroux, F; Combes, C; Galinat, S; Lassandre, S; Lopez, S; Teissier, MP, 2006) |
| "Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring." | 1.35 | Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. ( Louro, T; Matafome, P; Monteiro, P; Nunes, E; Seiça, R; Sena, CM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, KF | 1 |
| Mak, MWH | 1 |
| Lao, VWN | 1 |
| Yip, HLK | 1 |
| Lau, WY | 1 |
| Wong, VTL | 1 |
| Zhou, Y | 1 |
| Hu, C | 1 |
| Zhao, X | 1 |
| Luo, P | 1 |
| Lu, J | 1 |
| Li, Q | 1 |
| Chen, M | 1 |
| Yan, D | 1 |
| Lu, X | 1 |
| Kong, H | 1 |
| Jia, W | 1 |
| Xu, G | 1 |
| Betteridge, DJ | 1 |
| Vergès, B | 1 |
| Archambeaud-Mouveroux, F | 1 |
| Lopez, S | 1 |
| Combes, C | 1 |
| Lassandre, S | 1 |
| Amaniou, M | 1 |
| Teissier, MP | 1 |
| Galinat, S | 1 |
| Sena, CM | 1 |
| Louro, T | 1 |
| Matafome, P | 1 |
| Nunes, E | 1 |
| Monteiro, P | 1 |
| Seiça, R | 1 |
1 trial available for gliclazide and Dyslipidemias
| Article | Year |
|---|---|
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2005 |
4 other studies available for gliclazide and Dyslipidemias
| Article | Year |
|---|---|
Immune-mediated necrotising myopathy is a rare statin-associated adverse effect: a case report.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Gliclazid | 2020 |
Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography-Mass Spectrometry Method.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Eicosapentaenoic Acid; Female; Gas Chro | 2018 |
[Rhabdomyolysis induced by fenofibrate monotherapy].
Topics: Diabetes Mellitus; Drug Interactions; Dyslipidemias; Fenofibrate; Follow-Up Studies; Gliclazide; Hum | 2006 |
Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcholine; Animals; Antioxidants; Body Weight; Deoxyguanosine; Diab | 2009 |